Myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD): Diagnostic criteria

Overview

This microlearning reviews myelin oligodendrocyte glycoprotein antibody-associated disease, or MOGAD, with a focus on the 2023 International MOGAD Panel diagnostic criteria. This lesson explains how the clinical presentation, MOG-IgG result, supporting features, and exclusion of alternative diagnoses work together.

Learning objectives

  • Identify the three required components of the MOGAD diagnostic criteria.
  • Describe where MOGAD fits among CNS demyelinating diseases.
  • Explain the purpose of MOG-IgG testing.
  • Recognize supporting MRI and clinical features.
  • Identify findings that suggest an alternative diagnosis.

Intended audience

This activity is intended for neurologists, neuroimmunologists, neuro-ophthalmologists, neurology residents and fellows, advanced practice providers, and laboratory professionals involved in the evaluation and diagnosis of patients with suspected central nervous system demyelinating disorders.

Questions?

Contact us: mcleducation@mayo.edu

MCL Education

This post was developed by our Education and Technical Publications Team.